Drug Compounding Facility Initiates Voluntary Recall after FDA Reveals Contamination Risk
August 8, 2014 | Strategic Insights for Ambulatory Care
If healthcare facilities have any sterile drug products in their possession that were distributed from Unique Pharmaceuticals Ltd. of Temple, Texas, the drug products should be immediately quarantined to ensure that they are not used on patients, states a July 23, 2014, press release from the U.S. Food and Drug Administration (FDA). According to the press release, the compounding and outsourcing facility has announced a voluntary recall of all nonexpired drug products produced for sterile use, as these products may be contaminated and could cause potentially life-threatening infections or death.
Ambulatory Care CenterAmbulatory Surgery CenterAssisted-living FacilityBehavioral Health FacilityDialysis FacilityEmergency DepartmentEndoscopy FacilityHome CareHospiceHospital InpatientHospital OutpatientImaging CenterIndependent Living FacilityPhysician PracticeRehabilitation FacilityShort-stay FacilitySkilled-nursing FacilitySubstance Abuse Treatment FacilityTrauma Center